Bursa Postgraduate Hospital
15
0
0
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
6.7%
1 terminated/withdrawn out of 15 trials
93.3%
+6.8% vs industry average
27%
4 trials in Phase 3/4
7%
1 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
A Novel Technique for Percutaneous Mitral Paravalvular Leak Closure: LBBAP Lead Assisted Ventricular Septal Way
Role: lead
Effects of Upgrading From Right Ventricular Pacing to Cardiac Resynchronization Therapy and Comparison With Dual-Chamber Defibrillator
Role: lead
Lead Extraction With Manual Traction
Role: lead
Evaluation Of The Effect Of SGLT-2 Inhibitors On Atrial Fibrillation Recurrence In Diabetic Patients
Role: lead
Nitrate - Clopidogrel - Acute Coronary Syndrome
Role: lead
Rivaroxaban - Percutaneous Coronary Intervention
Role: lead
Safety And Efficacy Results of Percutaneous Renal Stent Implantation in Ectatic and Aneurysmatic Coronary Arteries
Role: lead
Bursa Postgraduate Hospital Department of Cardiology
Role: lead
The Effect of Whole Blood Viscosity on Contrast-Induced Nephropathy Development in Patients Undergoing Percutaneous Coronary Intervention
Role: lead
The Effect of Contrast Agents on the Anticoagulant Properties of Oral Factor Xa Inhibitors
Role: lead
Eosinophil and Anticoagulation in COVID-19 Patients
Role: lead
(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention)
Role: lead
Renal Denervation in Patients With Advanced Heart Failure
Role: lead
The Prognostic Significance of a Fragmented QRS Complex After Primary Percutaneous Coronary Intervention
Role: lead
The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance
Role: lead
All 15 trials loaded